BIOCELTIX S.A. ZY -10 (F:XI3) — Market Cap & Net Worth
Market Cap & Net Worth: BIOCELTIX S.A. ZY -10 (XI3)
BIOCELTIX S.A. ZY -10 (F:XI3) has a market capitalization of $89.73 Million (€76.75 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #19711 globally and #1810 in its home market, demonstrating a 1.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCELTIX S.A. ZY -10's stock price €17.60 by its total outstanding shares 5532253 (5.53 Million). Review XI3 current and long-term liabilities to assess the company's total debt and financial obligations.
BIOCELTIX S.A. ZY -10 Market Cap History: 2021 to 2026
BIOCELTIX S.A. ZY -10's market capitalization history from 2021 to 2026. Data shows growth from $71.15 Million to $113.83 Million (20.55% CAGR).
BIOCELTIX S.A. ZY -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCELTIX S.A. ZY -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of XI3 by Market Capitalization
Companies near BIOCELTIX S.A. ZY -10 in the global market cap rankings as of June 19, 2026.
Key companies related to BIOCELTIX S.A. ZY -10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
BIOCELTIX S.A. ZY -10 Historical Marketcap From 2021 to 2026
Between 2021 and today, BIOCELTIX S.A. ZY -10's market cap moved from $71.15 Million to $ 113.83 Million, with a yearly change of 20.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €113.83 Million | -27.72% |
| 2025 | €157.49 Million | +36.49% |
| 2024 | €115.39 Million | -8.51% |
| 2023 | €126.12 Million | +141.34% |
| 2022 | €52.26 Million | -26.55% |
| 2021 | €71.15 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of BIOCELTIX S.A. ZY -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.73 Million USD |
| MoneyControl | $89.73 Million USD |
| MarketWatch | $89.73 Million USD |
| marketcap.company | $89.73 Million USD |
| Reuters | $89.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more